Study of HSK46575 for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug, HSK46575, for men with metastatic castration-resistant prostate cancer that has worsened after hormone therapy and chemotherapy. The goal is to see if it can help slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Men aged 18 or older
- Prostate cancer that has spread to bones or soft tissue and is still growing despite hormone therapy
- Must have tried at least one hormone therapy and one chemotherapy, or be unable to tolerate chemotherapy
- Good overall health (able to care for yourself and out of bed more than half the day)
- No major heart, liver, or kidney problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, SHR-4394, for men with prostate cancer that has spread to other parts of the body and is no longer responding to current treatments. The goal is to see if this drug can help slow down the cancer.
This trial tests a combination of two experimental drugs, HS-20093 and HRS-5041, for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if this new treatment can help control the cancer when other treatments have stopped working.
This trial tests an experimental new drug (GSK5471713) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It is for people who have already tried certain hormone treatments and chemotherapy.
This trial is testing an investigational drug, HRS-7525, for men with advanced prostate cancer that has spread to other parts of the body. The goal is to see if the drug is safe and effective.
This trial tests a new tablet called HRS-5041 combined with other anti-cancer treatments for men with advanced prostate cancer that has not responded to previous therapies. It aims to see how well the combination works and if it is safe.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
Hear when a new m CRPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.